Funding
Genesis AI Raises $500M to Take Eno From Dexterity Demos to Deployment
Genesis AI raised a $500 million Series A at a $3.5 billion post-money valuation to expand physical-AI training and deploy its wheeled Eno robot. The round is verified; broad commercial deployment is still ahead.
Genesis AI has raised a $500 million Series A at a $3.5 billion post-money valuation, one of the largest early-stage robotics rounds yet. The company says the money will expand physical-AI training, dexterous manipulation, and production of Eno, its wheeled two-arm general-purpose robot.
The capital is real; broad deployment is not yet. Genesis told Reuters that a small number of robots are being tested with customers, including work connected to LG CNS, while a wider rollout is expected in 2027. That distinction matters more than the headline valuation.
Key Stats
$500M
Series A
$3.5B
Post-money valuation
2027
Wider rollout target
30–40
Eno units built
What Genesis Announced
Genesis announced the financing on November 17. Premji Invest, Khosla Ventures, and Eclipse co-led the round. Other participants named by the company include Durable Capital Partners, T. Rowe Price Associates, Bpifrance, HSG, NVIDIA, AMD Ventures, Zoom, Samsung Next, and Ericsson. Individual investors include Eric Schmidt, Eric Yuan, Jerry Yang, Xavier Niel, and former Tesla CFO Zach Kirkhorn.
The company says the proceeds will support large-scale data acquisition and training, expand the range of physical tasks its systems can perform, improve manipulation, grow the team, and accelerate real-world deployment. Those goals fit Genesis's full-stack strategy: it develops the robot, dexterous hands, training gloves, simulation environment, data engine, and GENE robotics foundation model together.
The round brings Genesis's disclosed funding to roughly $605 million after the $105 million seed financing announced in 2025. A large Series A does not establish product-market fit, but it gives the company unusually deep resources to attack the expensive integration problems between robot hardware, data collection, model training, manufacturing, and field support.
Market reality check
Genesis told TechCrunch it has built 30 to 40 Eno units and is piloting with a handful of undisclosed customers, while Reuters reported a 2027 wider-rollout target. The company has not published how many units are in customer pilots, uptime, interventions per hour, paid task economics, production capacity, or customer renewal data. The financing is verified; deployment scale remains early.
Why Eno Matters to the Humanoid Market
Eno is relevant to humanoid robotics precisely because Genesis rejects the full humanoid body plan. The machine uses a wheeled base, two arms, an adjustable body, and human-scale hands. Genesis argues that general-purpose work depends more on reach, dexterity, perception, and task intelligence than on legs, a head, or a face.
That design narrows the first deployment domain. Wheels are efficient and stable on factory and warehouse floors but cannot match legs on stairs, rough terrain, or heavily cluttered spaces. Genesis is trading mobility breadth for simpler locomotion and more engineering focus on manipulation. If Eno can perform useful work with lower hardware and supervision costs, it would pressure bipedal vendors to prove where legs generate measurable customer value.
Reuters reported that Genesis is testing a small number of robots with customers and has a partnership with LG CNS around manufacturing and logistics. The company expects a wider customer rollout in 2027 and is initially prioritizing the United States, including U.S. supply-chain and contract-manufacturing relationships. Those are concrete commercialization signals, but they remain plans and early tests rather than a scaled operating fleet.
| Signal | What is known | What remains undisclosed |
|---|---|---|
| Capital | $500M Series A; $3.5B post-money valuation | Runway, milestone schedule, and capital split |
| Customers | Small tests; LG CNS partnership named | Paid sites, fleet counts, renewals, and ROI |
| Product | Eno mobile manipulator plus integrated AI stack | Price, runtime, uptime, and production capacity |
| Timeline | Broader customer rollout targeted for 2027 | Delivery cadence and acceptance criteria |
The Dexterity Bet
Genesis is concentrating on hands and manipulation because many valuable industrial tasks are limited less by mobility than by contact-rich work: packing, cable handling, lab procedures, sorting, kitting, machine tending, and manipulating irregular objects. The company collects human demonstration data with sensor-equipped gloves intended to map hand motion and force signals into robot training data.
TechCrunch observed a demonstration in which robotic arms packed boxes, folded a carton, applied tape, and handled a label. The system completed the workflow, but a repeat run also produced a dropped box and difficulty peeling a label. Genesis also said its current dexterous hands last only a few weeks of regular work before replacement. Those details show both capability and the remaining reliability and maintenance gap. A customer buys the denominator, not the highlight reel: total attempts, failures, recovery behavior, component life, and labor required to keep the system productive.
The new funding can accelerate the data and iteration loop, but money does not remove the core deployment tests. Genesis still has to show that learned dexterity survives new object lots, lighting changes, tool wear, network faults, maintenance cycles, and the long tail of customer environments.
What to Watch Next
The next meaningful disclosure should be operational rather than financial. Watch for a named customer site, a defined production task, robots in service, task success rate, interventions per hour, operating hours, safety controls, and a delivery timetable. A 2027 rollout only becomes commercially meaningful when those details appear.
Also watch whether Genesis separates model performance from Eno performance. A manipulation policy running on fixed arms can prove important software capability, but it does not automatically establish that the mobile robot can navigate, position itself, manipulate, recover, and work safely as one product. Whole-system evidence is the standard that matters.
Bottom Line
Genesis AI's $500 million Series A is a major physical-AI financing event and a strong vote for dexterous mobile manipulation. It is not proof that Eno is ready for broad deployment. The company now has the capital to test its anti-humanoid thesis at scale; the next phase will be judged by customer tasks, reliability, supervision, and economics rather than valuation.